Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice
- PMID: 11250889
- PMCID: PMC145532
- DOI: 10.1093/emboj/20.6.1223
Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice
Abstract
Vascular endothelial growth factor receptor-3 (VEGFR-3) has an essential role in the development of embryonic blood vessels; however, after midgestation its expression becomes restricted mainly to the developing lymphatic vessels. The VEGFR-3 ligand VEGF-C stimulates lymphangiogenesis in transgenic mice and in chick chorioallantoic membrane. As VEGF-C also binds VEGFR-2, which is expressed in lymphatic endothelia, it is not clear which receptors are responsible for the lymphangiogenic effects of VEGF-C. VEGF-D, which binds to the same receptors, has been reported to induce angiogenesis, but its lymphangiogenic potential is not known. In order to define the lymphangiogenic signalling pathway we have created transgenic mice overexpressing a VEGFR-3-specific mutant of VEGF-C (VEGF-C156S) or VEGF-D in epidermal keratinocytes under the keratin 14 promoter. Both transgenes induced the growth of lymphatic vessels in the skin, whereas the blood vessel architecture was not affected. Evidence was also obtained that these growth factors act in a paracrine manner in vivo. These results demonstrate that stimulation of the VEGFR-3 signal transduction pathway is sufficient to induce specifically lymphangiogenesis in vivo.
Figures
![None](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/145532/bin/cde137f1.gif)
![None](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/145532/bin/cde137f2.gif)
![None](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/145532/bin/cde137f3.gif)
![None](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/145532/bin/cde137f4.gif)
![None](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/145532/bin/cde137f5.gif)
![None](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/145532/bin/cde137f6.gif)
![None](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/145532/bin/cde137f7.gif)
Similar articles
-
Vascular endothelial growth factors C and D and their VEGFR-2 and 3 receptors in blood and lymphatic vessels in healthy and arthritic synovium.J Rheumatol. 2002 Jan;29(1):39-45. J Rheumatol. 2002. PMID: 11824969
-
Lymphatic versus blood vascular endothelial growth factors and receptors in humans.Microsc Res Tech. 2001 Oct 15;55(2):108-21. doi: 10.1002/jemt.1162. Microsc Res Tech. 2001. PMID: 11596156 Review.
-
[Lymphangiogenesis and biological activity ov vascular endothelial growth factor-C].J Soc Biol. 1999;193(2):159-63. J Soc Biol. 1999. PMID: 10451350 Review. French.
-
VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane.Dev Biol. 1997 Aug 1;188(1):96-109. doi: 10.1006/dbio.1997.8639. Dev Biol. 1997. PMID: 9245515
-
A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.EMBO J. 1996 Jan 15;15(2):290-98. EMBO J. 1996. PMID: 8617204 Free PMC article.
Cited by
-
Biology and therapeutic targeting of vascular endothelial growth factor A.Nat Rev Mol Cell Biol. 2023 Nov;24(11):816-834. doi: 10.1038/s41580-023-00631-w. Epub 2023 Jul 25. Nat Rev Mol Cell Biol. 2023. PMID: 37491579 Review.
-
Acquired lymphedema: Molecular contributors and future directions for developing intervention strategies.Front Pharmacol. 2022 Oct 25;13:873650. doi: 10.3389/fphar.2022.873650. eCollection 2022. Front Pharmacol. 2022. PMID: 36386144 Free PMC article. Review.
-
The ambivalent nature of the relationship between lymphatics and cancer.Front Cell Dev Biol. 2022 Sep 7;10:931335. doi: 10.3389/fcell.2022.931335. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 36158182 Free PMC article. Review.
-
Fluorescent Tracers for In Vivo Imaging of Lymphatic Targets.Front Pharmacol. 2022 Jul 22;13:952581. doi: 10.3389/fphar.2022.952581. eCollection 2022. Front Pharmacol. 2022. PMID: 35935839 Free PMC article. Review.
-
Advances in 3D Vascularized Tumor-on-a-Chip Technology.Adv Exp Med Biol. 2022;1379:231-256. doi: 10.1007/978-3-031-04039-9_9. Adv Exp Med Biol. 2022. PMID: 35760994
References
-
- Achen M.G. et al. (2000) Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3. Eur. J. Biochem., 267, 2505–2515. - PubMed
-
- Aiello L.P., Pierce,E.A., Foley,E.D., Takagi,H., Chen,H., Riddle,L., Ferrara,N., King,G.L. and Smith,L.E. (1995) Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl Acad. Sci. USA, 92, 10457–10461. - PMC - PubMed
-
- Byrne C., Tainsky,M. and Fuchs,E. (1994) Programming gene expression in developing epidermis. Development, 120, 2369–2383. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous